Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 4.5% – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price rose 4.5% during trading on Friday . The company traded as high as $6.79 and last traded at $6.69. Approximately 3,680,020 shares were traded during trading, a decline of 74% from the average daily volume of 14,370,391 shares. The stock had previously closed at $6.40.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. KeyCorp lowered their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $8.75.

Recursion Pharmaceuticals Price Performance

The firm has a market cap of $2.55 billion, a P/E ratio of -4.27 and a beta of 0.85. The firm’s fifty day simple moving average is $6.90 and its 200 day simple moving average is $6.95. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. During the same period in the previous year, the company posted ($0.43) earnings per share. Recursion Pharmaceuticals’s quarterly revenue was up 147.6% on a year-over-year basis. As a group, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Insider Activity

In related news, CFO Michael Secora sold 15,000 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the transaction, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at approximately $11,487,173.46. This trade represents a 0.99 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total value of $87,455.08. Following the completion of the transaction, the director now owns 7,066,113 shares of the company’s stock, valued at approximately $53,985,103.32. This represents a 0.16 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,894 shares of company stock worth $317,139. 15.75% of the stock is currently owned by insiders.

Institutional Trading of Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Arkadios Wealth Advisors bought a new position in Recursion Pharmaceuticals during the fourth quarter valued at $84,000. Avanza Fonder AB purchased a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth about $580,000. Decker Retirement Planning Inc. bought a new position in Recursion Pharmaceuticals during the 4th quarter valued at about $26,000. 180 Wealth Advisors LLC raised its holdings in shares of Recursion Pharmaceuticals by 21.2% in the fourth quarter. 180 Wealth Advisors LLC now owns 31,230 shares of the company’s stock worth $211,000 after buying an additional 5,455 shares during the period. Finally, Wedmont Private Capital increased its stake in Recursion Pharmaceuticals by 10.6% in the fourth quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock worth $144,000 after purchasing an additional 2,000 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.